Published in Drug Discov Today on May 03, 2008
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
MicroRNAs and cardiac pathology. Nat Rev Cardiol (2009) 2.50
A status report on RNAi therapeutics. Silence (2010) 2.18
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A (2012) 1.90
Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet (2009) 1.19
Cathepsin B as a cancer target. Expert Opin Ther Targets (2013) 1.19
Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett (2009) 1.07
Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol (2009) 1.01
Cardiac to cancer: connecting connexins to clinical opportunity. FEBS Lett (2014) 0.96
Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release (2013) 0.91
Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol (2009) 0.90
Topical delivery of siRNA into skin using SPACE-peptide carriers. J Control Release (2014) 0.88
Silencing viral microRNA as a novel antiviral therapy? J Biomed Biotechnol (2009) 0.88
Thermodynamics of RNA duplexes modified with unlocked nucleic acid nucleotides. Nucleic Acids Res (2010) 0.87
Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors. J Nucleic Acids (2012) 0.83
Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. Int J Nanomedicine (2014) 0.82
Microfluidic assembly of lipid-based oligonucleotide nanoparticles. Anticancer Res (2011) 0.82
Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. Skelet Muscle (2011) 0.82
Hydrolysis of bulged nucleotides in hybrids formed by RNA and imidazole-derivatized oligo-2'-O-methylribonucleotides. Nucleosides Nucleotides Nucleic Acids (2011) 0.81
Antisense oligonucleotide mediated knockdown of HOXC13 affects cell growth and induces apoptosis in tumor cells and over expression of HOXC13 induces 3D-colony formation. RSC Adv (2012) 0.81
Polymerase-endonuclease amplification reaction (PEAR) for large-scale enzymatic production of antisense oligonucleotides. PLoS One (2010) 0.79
Hepatic stellate cell-specific gene silencing induced by an artificial microRNA for antifibrosis in vitro. Dig Dis Sci (2009) 0.79
Bottom-up design of small molecules that stimulate exon 10 skipping in mutant MAPT pre-mRNA. Chembiochem (2014) 0.79
In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice. J Control Release (2012) 0.79
CrxRdy Cat: A Large Animal Model for CRX-Associated Leber Congenital Amaurosis. Invest Ophthalmol Vis Sci (2016) 0.79
Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges. J Control Release (2015) 0.78
Modulation of p53 expression using antisense oligonucleotides complementary to the 5'-terminal region of p53 mRNA in vitro and in the living cells. PLoS One (2013) 0.78
Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors. Mol Ther Nucleic Acids (2012) 0.78
Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis. Dig Dis Sci (2009) 0.78
The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer. PLoS One (2013) 0.78
Synthetic antisense oligodeoxynucleotides to transiently suppress different nucleus- and chloroplast-encoded proteins of higher plant chloroplasts. Plant Physiol (2011) 0.78
Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease. Clin Transl Med (2016) 0.77
Therapeutic and prevention strategies against human enterovirus 71 infection. World J Virol (2015) 0.77
Triplex-forming peptide nucleic acids induce heritable elevations in gamma-globin expression in hematopoietic progenitor cells. Mol Ther (2013) 0.76
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treat Rev (2016) 0.76
Tailoring of chronic lymphatic leukemia therapy. Am J Blood Res (2013) 0.75
Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity. Artif DNA PNA XNA (2016) 0.75
Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are? World J Gastroenterol (2014) 0.75
HDL and microRNA therapeutics in cardiovascular disease. Pharmacol Ther (2016) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 38.75
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
microRNAs: tiny regulators with great potential. Cell (2001) 11.23
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A (1978) 7.90
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
A viral microRNA functions as an orthologue of cellular miR-155. Nature (2007) 5.09
Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease. Curr Opin Genet Dev (2007) 4.00
Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem (2003) 3.67
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem (2002) 3.32
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Discovery and development of anticancer aptamers. Mol Cancer Ther (2006) 2.01
Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta (1999) 1.95
miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA (2007) 1.78
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2007) 1.76
Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol (2006) 1.69
Intermolecular exon ligation of the rRNA precursor of Tetrahymena: oligonucleotides can function as 5' exons. Cell (1985) 1.65
Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature (1994) 1.59
Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest (1996) 1.57
Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 1.54
Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev (2002) 1.51
Therapeutic potential for microRNAs. Adv Drug Deliv Rev (2007) 1.41
Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma. Oncogene (2006) 1.40
Aneuploidy and cancer: from correlation to causation. Contrib Microbiol (2006) 1.35
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation (2006) 1.35
MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets (2007) 1.32
Gene therapy progress and prospects: RNA aptamers. Gene Ther (2007) 1.30
Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev (2003) 1.28
SELEX experiments: new prospects, applications and data analysis in inferring regulatory pathways. Biomol Eng (2007) 1.27
Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol (2006) 1.23
Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets (2001) 1.17
Vitravene--another piece in the mosaic. Antisense Nucleic Acid Drug Dev (1998) 1.16
Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta (2006) 1.14
Fomivirsen. Drugs (1999) 1.13
RNA silencing: genomic defence with a slice of pi. Nature (2007) 1.12
Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther (2006) 1.10
Targeting transcription factors for cancer therapy. Curr Pharm Des (2005) 1.10
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc Natl Acad Sci U S A (2007) 1.10
Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides. Proc Natl Acad Sci U S A (1992) 1.06
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2006) 1.06
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther (2002) 1.02
Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther (2007) 1.02
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res (2004) 0.94
Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle (2006) 0.94
Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob Agents Chemother (1998) 0.93
DNA triple-helix formation at physiologic pH and temperature. Antisense Res Dev (1991) 0.91
Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr Pharm Des (2005) 0.90
Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments. Nucleic Acids Res (1997) 0.90
Potential roles of antisense technology in cancer chemotherapy. Oncogene (2000) 0.90
A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol (2007) 0.89
Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res (2006) 0.88
Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide. Antimicrob Agents Chemother (1999) 0.87
Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev (1997) 0.87
Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev (2007) 0.86
Discontinued drugs in 2005: oncology drugs. Expert Opin Investig Drugs (2006) 0.86
Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab Dispos (1997) 0.85
Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin Adv Hematol Oncol (2005) 0.84
Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs (2006) 0.84
Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases. Curr Pharm Biotechnol (2004) 0.83
Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci (2003) 0.83
Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin Rev Allergy Immunol (2004) 0.82
Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev (2001) 0.82
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin Cancer Res (2003) 0.81
Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev (1997) 0.80
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci (2003) 0.80
Large-scale economic synthesis of antisense phosphorothioate analogues of DNA for preclinical investigations. Ann N Y Acad Sci (1990) 0.79
Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy. Curr Pharm Des (2007) 0.79
Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J Infect Dis (1997) 0.79
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Invest New Drugs (2006) 0.79
Discontinued drugs in 2005: anti-infectives. Expert Opin Investig Drugs (2007) 0.78
Ribozymes as antiviral agents. Minerva Med (2004) 0.78
Anti-HIV activity of steric block oligonucleotides. Ann N Y Acad Sci (2006) 0.77
In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol (2006) 2.33
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem (2004) 1.93
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A (2003) 1.87
MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets (2005) 1.83
Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets (2004) 1.72
Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J (2008) 1.65
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res (2007) 1.60
The MDM2-p53 pathway revisited. J Biomed Res (2013) 1.52
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene (2005) 1.51
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res (2008) 1.47
Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front Pharmacol (2012) 1.35
RYBP stabilizes p53 by modulating MDM2. EMBO Rep (2008) 1.33
Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med (2008) 1.32
Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate (2008) 1.31
p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets (2005) 1.30
Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res (2005) 1.30
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res (2004) 1.25
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate (2003) 1.22
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res (2006) 1.22
MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer (2013) 1.17
In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res (2009) 1.13
Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol (2006) 1.13
Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One (2012) 1.09
Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett (2009) 1.07
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther (2006) 1.05
Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer (2009) 1.00
Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish. Int J Biochem Cell Biol (2011) 1.00
Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med Res Rev (2014) 0.98
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res (2003) 0.98
Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol (2009) 0.98
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One (2011) 0.96
miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets (2013) 0.96
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action. Breast Cancer Res Treat (2009) 0.95
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res (2004) 0.94
Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm (2011) 0.94
Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem (2009) 0.94
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs (2009) 0.93
Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs. Med Chem (2009) 0.93
Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol (2004) 0.93
Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther (2013) 0.91
Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog. Mar Drugs (2012) 0.91
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther (2006) 0.91
MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem (2010) 0.90
Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr Pharm Des (2005) 0.90
Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One (2008) 0.90
Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol (2007) 0.90
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med (2002) 0.90
Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun (2002) 0.90
Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J Biol Chem (2012) 0.88
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol (2008) 0.87
A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol (2006) 0.87
Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev (2007) 0.86
KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One (2012) 0.86
Mode conversion based on forward stimulated Brillouin scattering in a hybrid phononic-photonic waveguide. Opt Express (2014) 0.85
JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. PLoS One (2012) 0.85
CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun (2003) 0.85
Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol (2002) 0.85
Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets (2013) 0.85
Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB. Clin Cancer Res (2013) 0.84
Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res (2013) 0.84
Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther (2013) 0.84
Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs (2006) 0.84
T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate (2008) 0.84
Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. Mar Drugs (2010) 0.83
Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol (2007) 0.83
Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci (2003) 0.83
Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis (2013) 0.83
Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors. Eur J Drug Metab Pharmacokinet (2010) 0.83
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate (2006) 0.82
Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res (2002) 0.81
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer (2002) 0.81
Oncogenes as novel targets for cancer therapy (part III): transcription factors. Am J Pharmacogenomics (2005) 0.81
Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann N Y Acad Sci (2005) 0.80
Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis. Am J Pharmacogenomics (2005) 0.80
Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents. Curr Cancer Drug Targets (2013) 0.80
Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer. J Cell Mol Med (2011) 0.79
Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharmacol (2005) 0.79
Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem Anticancer Agents (2004) 0.79
Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ. Curr Cancer Drug Targets (2013) 0.79
Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer. Proteomics (2007) 0.78
Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother Pharmacol (2012) 0.78
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Int J Oncol (2002) 0.78
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother Pharmacol (2005) 0.77
Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent. Cancer Chemother Pharmacol (2005) 0.77
Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr (2014) 0.77
Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules. Am J Pharmacogenomics (2005) 0.77
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol (2007) 0.76
Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics (2005) 0.76
Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. Cancer Chemother Pharmacol (2005) 0.75
Analysis of acousto-optic interaction based on forward stimulated Brillouin scattering in hybrid phononic-photonic waveguides. Opt Express (2016) 0.75
Analysis of threshold current of uniaxially tensile stressed bulk Ge and Ge/SiGe quantum well lasers. Opt Express (2017) 0.75
Anti-cancer molecular targets of natural products. Curr Cancer Drug Targets (2013) 0.75
Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal (2006) 0.75
Antisense approaches in drug discovery and development. Prog Drug Res (2005) 0.75
Design and analysis of a CMOS-compatible distributed Bragg reflector laser based on highly uniaxial tensile stressed germanium. Opt Express (2017) 0.75
Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. Methods Mol Biol (2015) 0.75